<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532047</url>
  </required_header>
  <id_info>
    <org_study_id>20-31520</org_study_id>
    <nct_id>NCT04532047</nct_id>
  </id_info>
  <brief_title>In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases</brief_title>
  <acronym>IUERT</acronym>
  <official_title>In Utero Enzyme Replacement Therapy (ERT) for Prenatally Diagnosed Lysosomal Storage Disorders (LSDs).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aims to determine the the maternal and fetal safety and feasibility of in&#xD;
      utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because fetuses with these LSDs are at increased risk of serious perinatal morbidity and&#xD;
      mortality, particularly in the setting of Non-Immune Hydrops Fetalis (NIHF), the&#xD;
      administration of the approved enzyme therapy in utero has the potential to significantly&#xD;
      improve outcomes for affected fetuses. The perinatal death rate associated with NIHF ranges&#xD;
      from 30 to 75%, so development of an in utero approach to treatment could be of significant&#xD;
      benefit. The in utero period has been shown to be a time of relative fetal tolerance to&#xD;
      immune stimuli, and this tolerance may lead to improved response to ERT in situations where&#xD;
      postnatal initiation instead leads to antibody development and impaired response to&#xD;
      treatment. It is also probable that in some cases, initiation of ERT in utero leads to&#xD;
      improved neurodevelopmental outcomes if the replaced enzyme impacts the neurologic system&#xD;
      during critical periods of development.&#xD;
&#xD;
      This is a phase 1 clinical trial to determine the safety and feasibility of fetal enzyme&#xD;
      replacement therapy in fetuses with LSD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">April 2032</completion_date>
  <primary_completion_date type="Anticipated">April 2031</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>6 years</time_frame>
    <description>Adverse and serious adverse events including, but not limited to, death within 24 hours after the procedure, stillbirth, death prior to initial hospital discharge,increased response with antibody development above that expected with postnatal ERT, and serious related or serious unexpected adverse events exceeding those expected with the natural history of treated disease during the first five years of life, assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants to receive the full initial, weight-based dose of enzyme replacement therapy through the fetal umbilical vein, and subsequent doses throughout the pregnancy.</measure>
    <time_frame>6 years</time_frame>
    <description>full dose administration compared to the need to halt the intervention prior to administration of a full dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with the presence and levels of glycosaminoglycans (GAGs) in urine.</measure>
    <time_frame>6 years</time_frame>
    <description>Laboratory analysis of urine for GAG levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of participants with improvement or resolution of hydrops (if present).</measure>
    <time_frame>6 years</time_frame>
    <description>Improvement of hydrops via ultrasound and echocardiogram results (if present).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that show measured levels of antibodies against the enzyme.</measure>
    <time_frame>6 years</time_frame>
    <description>Laboratory analysis of blood to measure antibody levels.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants that show functional cardiac, growth, mobility, and neurocognitive function.</measure>
    <time_frame>6 years</time_frame>
    <description>ecogardiogram, skeletal survey, neurocognitve assessments such as Bayley III to assess cardiac, growth, mobility and neurocognitive function.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>MPS I</condition>
  <condition>MPS II</condition>
  <condition>MPS IVA</condition>
  <condition>MPS VI</condition>
  <condition>Mps VII</condition>
  <condition>Gaucher Disease, Type 2</condition>
  <condition>Gaucher Disease, Type 3</condition>
  <condition>Pompe Disease Infantile-Onset</condition>
  <condition>Wolman Disease</condition>
  <arm_group>
    <arm_group_label>Experimental: in utero enzyme replacement therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERT will be delivered in utero. Typically, the target of the procedure to administer in utero ERT will be the umbilical vein near the insertion of the umbilical cord into the placenta. The dose of the ERT will be dependent on the specific disease process and enzyme being replaced, and the estimated weight of the fetus. The dosage will be the same as the recommended weight-based postnatal dosing, adjusted for estimated fetal weight. IUERT will be repeated every 2-4 weeks, which is an interval consistent with the standard of care for IUTs (every 2-4 weeks) to avoid excessive access through the umbilical vein. This interval is also consistent with the half-life of each relevant enzyme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldurazyme (laronidase)</intervention_name>
    <description>Enzyme replacement therapy for lysosomal storage diseases</description>
    <arm_group_label>Experimental: in utero enzyme replacement therapy</arm_group_label>
    <other_name>Elaprase (idursulfase)</other_name>
    <other_name>Vimizim (elosulfase alfa)</other_name>
    <other_name>Naglazyme (galsulfase)</other_name>
    <other_name>Mepsevii (vestronidase alfa-vjbk)</other_name>
    <other_name>Lumizyme (alglucosidase alfa)</other_name>
    <other_name>Kanuma (sebelipase alfa)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Live male or female fetuses at 18 0/7 weeks to 34 6/7 weeks gestation&#xD;
&#xD;
          -  Diagnosis of one of the 8 included LSDs in utero by genetic or enzymatic analyses&#xD;
             performed on amniotic fluid, fetal blood, placental tissue, or other samples through&#xD;
             chorionic villus sampling (CVS), amniocentesis, cordocentesis, cell free fetal DNA, or&#xD;
             other procedures. In the event that parents are identified as genetic carriers for a&#xD;
             LSD, diagnostic testing for the fetus would be performed to confirm the diagnosis&#xD;
&#xD;
          -  Pregnant women age 18 years to 50 years, carrying a live male or female fetus at 18&#xD;
             0/7 weeks to 34 6/7 weeks gestation&#xD;
&#xD;
          -  Identified through the above listed means to be carrying a fetus with an LSD.&#xD;
&#xD;
          -  Ability to give written informed consent and comply with the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fetuses with a concurrent severe structural anomaly&#xD;
&#xD;
          -  Fetuses with an additional pathogenic genetic variant not related to the underlying&#xD;
             LSD that contribute a significant risk of morbidity or mortality.&#xD;
&#xD;
        Hydrops fetalis will not be an exclusion criterion because ERT has the possibility of&#xD;
        significant benefit in this situation.&#xD;
&#xD;
          -  Women with one or more significant comorbidities that would preclude fetal&#xD;
             intervention including, but not limited to:&#xD;
&#xD;
               1. inability to complete the procedure secondary to maternal body habitus or&#xD;
                  placental location&#xD;
&#xD;
               2. significant cardiopulmonary disease&#xD;
&#xD;
               3. mirror syndrome&#xD;
&#xD;
               4. end organ failure&#xD;
&#xD;
               5. altered mental status&#xD;
&#xD;
               6. placental abruption&#xD;
&#xD;
               7. active preterm labor&#xD;
&#xD;
               8. preterm premature rupture of membranes.&#xD;
&#xD;
          -  Mother will require therapeutic dosing of anticoagulation within 24 hours prior to or&#xD;
             following the intervention.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Maternal pregnant women of age 18-50, carrying a male or female fetus at 18 0/7 weeks to 34 6/7 weeks.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tippi MacKenzie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tippi MacKenzie, MD</last_name>
    <phone>415-476-4086</phone>
    <email>tippi.mackenzie@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romobia Hutchinson, MPA</last_name>
    <phone>415-476-9326</phone>
    <email>romobia.hutchinson@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romobia Hutchinson, MPA</last_name>
      <phone>415-476-9326</phone>
      <email>romobia.hutchinson@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Romobia Hutchinson, MPA</last_name>
      <phone>(415) 476-9326</phone>
      <email>romobia.hutchinson@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nguyen QH, Witt RG, Wang B, Eikani C, Shea J, Smith LK, Boyle G, Cadaoas J, Sper R, MacKenzie JD, Villeda S, MacKenzie TC. Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with Mucopolysaccharidosis type VII. Sci Transl Med. 2020 Feb 26;12(532). pii: eaay8980. doi: 10.1126/scitranslmed.aay8980.</citation>
    <PMID>32102934</PMID>
  </results_reference>
  <results_reference>
    <citation>Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Author Correction: Lysosomal storage diseases. Nat Rev Dis Primers. 2018 Oct 18;4(1):36. doi: 10.1038/s41572-018-0037-0.</citation>
    <PMID>30337566</PMID>
  </results_reference>
  <results_reference>
    <citation>Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999 Jan 20;281(3):249-54.</citation>
    <PMID>9918480</PMID>
  </results_reference>
  <results_reference>
    <citation>Azevedo AC, Schwartz IV, Kalakun L, Brustolin S, Burin MG, Beheregaray AP, Leistner S, Giugliani C, Rosa M, Barrios P, Marinho D, Esteves P, Valadares E, Boy R, Horovitz D, Mabe P, da Silva LC, de Souza IC, Ribeiro M, Martins AM, Palhares D, Kim CA, Giugliani R. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet. 2004 Sep;66(3):208-13.</citation>
    <PMID>15324318</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18(3):163-75. Review.</citation>
    <PMID>23510062</PMID>
  </results_reference>
  <results_reference>
    <citation>Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, Huang AC, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009 Dec;124(6):e1116-25. doi: 10.1542/peds.2008-3667.</citation>
    <PMID>19948615</PMID>
  </results_reference>
  <results_reference>
    <citation>Blitz MJ, Rochelson B, Sood M, Bialer MG, Vohra N. Prenatal sonographic findings in a case of Wolman's disease. J Clin Ultrasound. 2018 Jan;46(1):66-68. doi: 10.1002/jcu.22481. Epub 2017 Apr 4.</citation>
    <PMID>28374935</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai AC, Hung YW, Harding C, Koeller DM, Wang J, Wong LC. Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease. Am J Med Genet A. 2017 Sep;173(9):2500-2504. doi: 10.1002/ajmg.a.38333. Epub 2017 Jun 28.</citation>
    <PMID>28657663</PMID>
  </results_reference>
  <results_reference>
    <citation>Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, Chen YT, Rosenberg AS, Kishnani PS. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011 Aug;13(8):729-36. doi: 10.1097/GIM.0b013e3182174703.</citation>
    <PMID>21637107</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Tippi Mackenzie</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Wolman Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

